We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Thyroid Hormone Levels Linked to Liver Fibrosis in T2D

By LabMedica International staff writers
Posted on 04 Jul 2022
Print article
Image: Abbot Laboratories Free Thyroxine (FT4) Reagent Kit (Photo courtesy of Henry Schlein)
Image: Abbot Laboratories Free Thyroxine (FT4) Reagent Kit (Photo courtesy of Henry Schlein)

Nonalcoholic fatty liver disease (NAFLD) is a clinical pathological syndrome and one of its key characteristics is hepatic steatosis which can be caused by excessive accumulation of fat in the liver.

The liver plays a crucial role in the metabolism of cholesterol and triglycerides (TG). Meanwhile, thyroid hormones interact on hepatic lipid homeostasis through multiple pathways, including stimulation of free fatty acid delivery to the liver for re-esterification to TG, and increasing fatty acid β-oxidation, thereby affecting hepatic fat accumulation.

Endocrinologists at the Anhui Medical University (Anhui, China) carried out a retrospective analysis that included 586 participants, of whom 55.1% were women. They divided participants into groups 346 with and 240 without NAFLD. A NAFLD fibrosis score of > 0.676 served as the definition for progressive liver fibrosis, which the scientists used to categorize participants into two groups: those with (n = 93) and without (n = 493) progressive liver fibrosis.

After separation of serum, fasting blood glucose (FBG), blood fat, liver function, kidney function and albumin (ALB) were measured using an automatic biochemical analyzer (Hitachi, 7600–020, Tokyo, Japan). Fasting C-peptide (FCP) was detected using enzyme-linked immunosorbent assay Autolumo A2000 Plus (Autobio Diagnostics Co., Ltd, Zheng Zhou City, China). High-performance liquid chromatography was performed for the determination of glycosylated hemoglobin (HbA1c) and flow cytometry and the Sysmex XN9000 (Kobe, Japan) and for the determination of platelets (PLT). Chemiluminescence microparticle immunoassay (Abbott ARCHITECT i4000, Abbott Park, IL, USA) was used to measure FT3, FT4, TT3, TT4 and TSH.

The scientists reported that levels of free triiodothyronine, total triiodomethylamine and free T3/free thyroxine ratio were significantly increased whereas the free T4 level was decreased in the group with NAFLD compared with the group without NAFLD. Additionally, compared with participants without progressive liver fibrosis, those with progressive liver fibrosis demonstrated lower levels of free T3, free T4, total T3 and total T4. In logistic regression analysis, a positive relationship between free T3/free T4 ratio and NAFLD was observed, whereas a negative association was reported between free T4 level and NAFLD, and between the risk for progressive hepatic fibrosis and levels of free T4, total T3 and total T4.

The authors concluded that there is a close correlation between the abnormal thyroid hormone levels and liver fibrosis in type 2 diabetes patients. The prevalence of NAFLD increased following the increase of free T3; free T3/free T4 ratio and decrease of free T4. These results suggested that the change of thyroid hormone level in type 2 diabetes patients should be tested routinely for judging the patient’s condition and predicting the prognosis. The study was published on May 31, 2022 in the journal BMC Endocrine Disorders.

Related Links:
Anhui Medical University 
Hitachi 
Autobio Diagnostics Co., Ltd
Sysmex 
Abbott 

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.